Status:
COMPLETED
Surgical Resection for Hepatocellular Carcinoma
Lead Sponsor:
Dr Cipto Mangunkusumo General Hospital
Conditions:
Resectable Hepatocellular Carcinoma
Eligibility:
All Genders
Brief Summary
Hepatocellular carcinoma is a type of liver cancer and is one of the leading causes of global cancer death. Surgical resection of the afflicted areas of the liver is one of the treatment methods for t...
Detailed Description
Study design This is a retrospective cohort study. Treatment of Hepatocellular Carcinoma Patients in RSCM HCC patients are managed by a multidisciplinary team (MDT) consisting of hepatologists, radio...
Eligibility Criteria
Inclusion
- Patients undergoing liver resection in Cipto Mangunkusumo hospital due to a confirmed diagnosis of hepatocellular carcinoma from 2010 to 2021
Exclusion
- Patients undergoing liver resection in other hospitals were excluded, even though diagnosis or further care is done in Cipto Mangunkusumo hospital
- Patients with other malignancies
- Patients undergoing other treatment methods for hepatocellular carcinoma.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT06013657
Start Date
December 1 2021
End Date
June 1 2022
Last Update
August 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Cipto Mangunkusumo General Hospital
Jakarta Pusat, DKI Jakarta, Indonesia, 10440